Awaiting development: Guidance and quality standards

Showing 211 to 220 of 335

Guidance and quality standards awaiting development
Title	Type
PLX-PAD for treating muscle injury after arthroplasty for hip fracture in people 60 to 90 years [ID3989]	Technology appraisal guidance
Port Delivery Platform with ranibizumab for treating wet age-related macular degeneration [ID3983]	Technology appraisal guidance
Povorcitinib for treating moderate to severe active hidradenitis suppurativa after a TNF-alpha inhibitor [ID6569]	Technology appraisal guidance
Prevention of dementia	Quality standard
Pridopidine for treating Huntington's disease [ID6525]	Technology appraisal guidance
Primary hyperparathyroidism	Quality standard
Prognostic tests for multiple myeloma	HealthTech guidance
Prostate cancer (hormone relapsed, homologous recombination deficiency, metastatic) – rucaparib (after 1 therapy) [ID6127]	Technology appraisal guidance
PXT3003 for treating Charcot-Marie-Tooth disease type 1A in people aged 16 and over [ID1439]	Technology appraisal guidance
Ranibizumab port delivery system for treating diabetic macular oedema [ID6137]	Technology appraisal guidance